.jetcityimage/iStock Editorial via Getty Images Morgan Stanley has actually decided on Eli Lilly (NYSE: LLY) as its own leading biopharma pick for 2025 and measured an additional nine titles in the room as obese. The financial investment financial institution said in a keep in mind that it continues to strongly believe “diabesity is actually set to end up being.